Erythropoietin - Protein Sciences
Alternative Names: rEPO - Protein SciencesLatest Information Update: 31 Oct 2021
At a glance
- Originator Protein Sciences Corporation
- Class Antianaemics; Polyethylene glycols; Recombinant erythropoietins; Recombinant fusion proteins
- Mechanism of Action Erythropoiesis stimulants; Erythropoietin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Anaemia
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Anaemia in USA
- 28 Aug 2017 Protein Sciences Corporation has been acquired by Sanofi
- 31 Mar 2008 This programme is still in active development